Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine

References

• Koff RS. Review article: vaccination and viral hepatitis – current status and future prospects. Aliment Pharmacol. Ther.26(10), 1285–1292 (2007).
   PubMedGoogle Scholar
• World Health Organization (WHO). Hepatitis A vaccines. Wkly Epidemiol. Rec.75, 38–43 (2000).
   PubMedGoogle Scholar
• Centers for Disease Control (CDC). Hepatitis A. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (9th Edition). Atkinson W, Hamborsky J, McIntyre L, Wolfe S (Eds). Public Health Foundation, Washington DC, USA 193–206 (2006).
   Google Scholar
• Centers for Disease Control (CDC). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-7), 1–23 (2006).
   PubMedGoogle Scholar
• World Health Organization (WHO). WHO position paper on the use of hepatitis B vaccines. Wkly Epidemiol. Rec.255–263 (2004).
   PubMedGoogle Scholar
• Impfempfehlungen der ständigen impfkommission (STIKO) an RKI Epidemiologisches Bulletin Nr 2, Robert Koch Institut (2000).
   Google Scholar
• Salisbury DM, Begg NT. Immunisation against infectious disease. London: HM Stationery Office 95–108 (1996).
   Google Scholar
• Sezer S, Özdemir FN, Güz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc.32, 607 (2000).
   PubMed Web of Science ®Google Scholar
• Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am. J. Nephrol.16, 95 (1996).
   PubMed Web of Science ®Google Scholar
• Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J. Infect. Dis.148, 1033–1039 (1983).
   PubMed Web of Science ®Google Scholar
• WHO Expanded Programme on Immunization, Global Advisory Group. Wkly Epidemiol. Rec.3, 11–16 (1992).
   Google Scholar
• Safary A, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine18, 57–67 (2000).
   Google Scholar
• Germinario C, Lopalco PL, Chicanna M, Da Villa G. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine18(Suppl. 1), S83–S85 (2000).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine21(7–8), 698–701 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R. Update from Israel, the first country to adopt hepatitis A universal immunization program. Proceedings of the 3rd World Congress Pediatric Infectious Diseases, Santiago, Chile, November 19–23 (2002).
   Google Scholar
• Keystone JS, Hershey JH. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule. Int. J. Infect. Dis. (2007) DOI:10.1016/j.ijid.2007.04.012.
   PubMedGoogle Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev. Vaccines33, 249–267 (2004).
   Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine17(13–14), 1657–1662 (1999).
   PubMed Web of Science ®Google Scholar
• Joines RW, Blatter M, Abraham B et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine19(32), 4710–4719 (2001).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med. Infect. Dis.5, 79–84 (2007).
   PubMedGoogle Scholar
• Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated schedule. J. Travel Med.14(1), 9–15 (2007).
   PubMed Web of Science ®Google Scholar
• Hohler T, Groeger-Bicanic G, Hoet B, Stoffel M. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine25, 1503–1508 (2007).
   PubMed Web of Science ®Google Scholar
• Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine21(25–26), 3623–3628 (2003).
   PubMed Web of Science ®Google Scholar
• Nothdurft HD, Aumuller H, Aumuller R et al. A breakthrough case of hepatitis A disease following a full vaccination schedule of three doses of a combined hepatitis A and B vaccine. Vaccine22, 592–593 (2004).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K, Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine22, 303–304 (2004).
   PubMedGoogle Scholar
• Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine24, 5509–5515 (2006).
   PubMed Web of Science ®Google Scholar
• Abraham B, Baine Y, De-Clercq N et al. Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine. Antiviral Res.53(1), 63–73 (2002).
   PubMedGoogle Scholar
• Höhler T, Reuss E, Evers N et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet360(9338), 991–995 (2002).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med. Infect. Dis.5, 171–175 (2007).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? J. Travel Med.11(30), 179–180 (2004).
   PubMedGoogle Scholar
• Van Damme P, Banatvala J, Fay O et al. International Consensus Group on Hepatitis A Virus Immunity: hepatitis A booster: is there a need? Lancet362, 1065–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Banatvala JE, Van Damme P. Hepatitis B vaccine – do we need boosters? J. Viral Hepat.10, 1–6 (2003).
   PubMed Web of Science ®Google Scholar
• Banatvala J, Kane M, Da Villa G et al. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet355, 561–565 (2000).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med. Infect. Dis.5, 79–84 (2007).
   PubMedGoogle Scholar
• Beran J. Combined two-dose hepatitis A and B vaccine (AmBirix). Drugs63(2), 214–215 (2003).
   Web of Science ®Google Scholar
• Diaz-Mitoma F, Law B, Parsons J. A combined vaccine against hepatitis A and B in children and adolescents. Pediatr. Infect. Dis. J.18, 109–114 (1999).
   PubMedGoogle Scholar
• Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol.65, 6–13 (2001).
   PubMed Web of Science ®Google Scholar
• Van der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children aged one to eleven years. Pediatr. Infect. Dis. J.19(9), 848–853 (2000).
   PubMed Web of Science ®Google Scholar
• Burgess MA, Rodger AJ, Waite SHA, Collard F. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomized study. Vaccine19, 4835–4841 (2001).
   PubMed Web of Science ®Google Scholar
• Levie K, Beran J, Collard F, Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12–15 years. Vaccine20, 579–2584 (2002).
   Google Scholar
• Roberton D, Marshall H, Nolan TM et al. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children. Vaccine23, 5099–5105 (2005).
   PubMed Web of Science ®Google Scholar
• Kurugöl Z, Mutlubas F, Ozacar T. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6–15 years. Vaccine23(22), 2876–2880 (2005).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev. Vaccines3(3), 249–267 (2004).
   PubMedGoogle Scholar
• Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs63(23), 2625–2649 (2003).
   PubMed Web of Science ®Google Scholar
• Jarvis B, Figgitt DP. Combined two-dose hepatitis A and B vaccine (AmBirix). Drugs63(2), 207–213 (2003).
   PubMedGoogle Scholar
• Loscher T, Keystone JS, Steffen R. Vaccination of travellers against hepatitis A and B. J. Travel Med.6(2), 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Steffen R. Immunization against Hepatitis A and Hepatitis B infections. J. Travel Med.8(Suppl. 1), S9–S16 (2001).
   PubMedGoogle Scholar
• Keefe E. Hepatitis A in patients with chronic liver disease – severity of illness and prevention with vaccination. J. Viral Hepat.7(Suppl. 1), 15–17 (2000).
   Google Scholar
• Pramoolsinsap CJ. Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or Hepatitis C virus-related chronic liver diseases in Thailand. J. Viral Hepat.7(Suppl. 1), 11–12 (2000).
   PubMedGoogle Scholar
• Genton B, D’Acremont V, Furrer HJ, Hatz C, Loutan L. Hepatitis A vaccines and the elderly. Travel Med. Infect. Dis.4(6), 303–312 (2006).
   PubMedGoogle Scholar
• Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injection drug users: a systematic review. Lancet7(10), 667–674 (2007).
   Google Scholar
• Yoneyama T, Kiyohara T, Shimasaki N et al. Rapid and real-time detection of hepatitis A virus by reverse transcription loop-mediated isothermal amplification assay. J. Virol. Methods145(2), 162–168 (2007).
   PubMed Web of Science ®Google Scholar
• Kafatos G, Anastassopoulou C, Nardone A et al. The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. J. Viral Hepat.14(4), 260–268 (2007).
   PubMedGoogle Scholar
• European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity ?. Lancet355, 561–565 (2000).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Banatvala J, Fay O et al. Hepatitis A booster vaccination: is there a need? Lancet362, 1065–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Mansoor OD, Salama P. Should hepatitis B vaccine be used for infants? Expert Rev. Vaccines61, 29–33 (2007).
   Google Scholar
• Nothdurft HD, Zuckerman J, Stoffel M, Dieussaert I, Van Damme P. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers. J. Travel Med.11, 260–261 (2004).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P, Collard F, Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11–18 years. Scand. J. Gastroenterol.34(12), 1236–1240 (1999).
   PubMedGoogle Scholar
• Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol. Belg.61(2), 175–182 (1998).
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm. Rep.55(RR-16), 1–33 (2006).
   PubMedGoogle Scholar